Comera Life Sciences to Present at 22nd Annual PepTalk Conference
January 12 2023 - 4:15PM
Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Company” or
“Comera”), a life sciences company developing a new generation of
bio-innovative biologic medicines to improve patient access, safety
and convenience, today announced it will present at the 22nd Annual
PepTalk Conference, in San Diego on Wednesday, Jan. 18, 2023 at
5:15 p.m. PT. The conference will run from Monday, Jan. 16 through
Friday, Jan. 20.
Subhashchandra Naik, Ph.D., Senior Research
Scientist at Comera, will share data on viscosity reduction and
stabilization using Comera’s leading SQore™ platform technology
excipients, which enable development of highly concentrated
monoclonal antibody (mAb) formulations for subcutaneous
administration. The presentation is titled “Biophysical
characterization of excipient combinations for mAb formulation
development.”
Robert Mahoney, Ph.D., Chief Scientific Officer
at Comera, commented, “Comera’s SQore platform has more than 200
excipient compounds that have been developed with high precision
science and engineering. This robust platform is being used to
enable monoclonal antibodies across major therapeutic indications
to be delivered subcutaneously, with the goal of providing patients
the freedom of self-injectable care.”
About Comera Life
SciencesLeading a compassionate new era in medicine,
Comera Life Sciences is applying a deep knowledge of formulation
science and technology to transform essential biologic medicines
from intravenous (IV) to subcutaneous (SQ) forms. The goal of this
approach is to provide patients with the freedom of self-injectable
care, reduce institutional dependency and to put patients at the
center of their treatment regimen.
To learn more about the Comera Life Sciences
mission, as well as the proprietary SQore™ platform, visit
https://comeralifesciences.com/.
Forward-Looking Statements This press release
includes “forward-looking statements” within the meaning of the
federal securities laws. These forward-looking statements generally
are identified by the words “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“will continue,” “will likely result,” and similar expressions.
Forward-looking statements are predictions, projections and other
statements about future events like the anticipated use of proceeds
from the private placement that are based on current expectations
and assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release, including, but not limited to: risks that the recently
completed business combination disrupts the Company’s current plans
and ability to retain its employees; the Company’s ability to
maintain the listing of its securities on the Nasdaq Capital
Market; the effect of the COVID-19 pandemic on the Company’s
business; the price of the Company’s securities may be volatile due
to a variety of factors, including changes in the competitive and
highly regulated industries in which the Company plans to operate,
variations in performance across competitors, changes in laws and
regulations affecting the Company’s business and changes in the
capital structure; the ability to implement business plans,
forecasts, and other expectations and identify and realize
additional opportunities; the risk of downturns and the possibility
of rapid change in the highly competitive industry in which the
Company operates; the risk that the Company and its current and
future collaborators are unable to successfully develop and
commercialize the Company’s products or services, or experience
significant delays in doing so; the risk that we will be unable to
continue to attract and retain third-party collaborators, including
collaboration partners and licensors; the risk that the Company may
never achieve or sustain profitability; the risk that the Company
will need to raise additional capital to execute its business plan,
which may not be available on acceptable terms or at all; the risk
that the Company experiences difficulties in managing its growth
and expanding operations; the risk that third-party suppliers and
manufacturers are not able to fully and timely meet their
obligations; the risk that the Company is unable to secure or
protect its intellectual property; the risk that the Company is
unable to secure regulatory approval for its product candidates;
general economic conditions; and other risks and uncertainties
indicated in the Quarterly Report on Form 10-Q filed with the SEC
on November 14, 2022 under “Risk Factors” and in other filings that
have been made or will be made with the SEC. The foregoing list of
factors is not exhaustive. You should carefully consider the
foregoing factors and the other risks and uncertainties described
in the “Risk Factors” section of Comera’s Quarterly Report on Form
10-Q filed with the SEC on November 14, 2022, and other documents
filed by Comera from time to time with the SEC. These filings
identify and address other important risks and uncertainties that
could cause actual events and results to differ materially from
those contained in the forward-looking statements. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and Comera assumes no obligation and does not intend to update or
revise these forward-looking statements, whether as a result of new
information, future events, or otherwise. Comera can give no
assurance that it will achieve its expectations.
Contacts
Comera Investor John Woolford ICR Westwicke
John.Woolford@westwicke.com
Comera Press Jon YuICR
WestwickeJon.Yu@westwicke.com
Comera Life Sciences (NASDAQ:CMRA)
Historical Stock Chart
From May 2024 to Jun 2024
Comera Life Sciences (NASDAQ:CMRA)
Historical Stock Chart
From Jun 2023 to Jun 2024